Cameg Pharmaceutical Import Profile — Cote D Ivoire (DGFT 2022–2026)

Name: Cameg Pharmaceutical Import Records from India — 8 Products, $5.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cameg — Pharmaceutical Importer Profile (2026) | 8 Products, $5.3M Trade | TransData Nexus

Cameg

Pharmaceutical Importer · Cote D Ivoire · Analgesics & Antipyretics Focus · $5.3M Total Trade · DGFT Verified

Cameg is a pharmaceutical importer based in Cote D Ivoire with a total trade value of $5.3M across 8 products in 5 therapeutic categories. Based on 115 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Cameg sources from 37 verified Indian suppliers, with Sidhaant Life Sciences Private Limited accounting for 34.5% of imports.

Cameg — Import Portfolio & Supplier Network

Cameg import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Cameg?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sidhaant Life Sciences Private Limited	$5.7M	188	34.5%
Fourrts (india) Laboratories Private Limited	$4.1M	131	24.8%
Fourrts I Laboratories Private Limited	$1.3M	34

What Formulations Does Cameg Import?

Formulation	Value	Ships
Pharmaceutical products,phloroglucinol	$327.0K	7
Paracetamol tablets BP 500MG qty	$300.0K	6
Ibuprofen oral suspension 100MG/5ML bat.	$200.0K	4
Gauze swab sterile BP 10x10 cms x16	$150.0K	3
Metronidazole tablets BP 250MG ( qty - 10800 x 100 x 10s )	$150.0K	3
Amoxicillin tablets oral suspension	$137.0K	3
Ceftriaxone 500MG iv/im powder for injection batch no-24cei011, 24cei012, 24cei013, 24cei014, mfg dt. feb-24, exp dt.	$121.6K	3
Fluconazole capsules 150MG - batch	$110.6K	8
Ceftriaxone for injection USP & sterilised water for injection	$110.2K	3
Quinine dihydrochloride sterile	$107.7K	4
Cotrimoxazole tablet BP	$101.9K	3
Paracetamol tablets BP 500MG qty	$100.0K	2
Gentamycine 0.3 % eye drops 5ML batch	$100.0K	2
Drugs and pharmaceuticals harmless	$100.0K	2
Phloroglucinol tablets 80 MG (other	$100.0K	2

Cameg imports 489 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Paracetamol	Analgesics & Antipyretics	$2.5M	50	0.7%	4
2	Ceftriaxone	Advanced Antibiotics	$850.0K	17	0.3%	17
3	Sulfamethoxazole	Advanced Antibiotics	$400.0K	8	2.0%	3
4	Trimethoprim	Advanced Antibiotics	$400.0K	8	1.5%	3
5	Griseofulvin	Advanced Antifungals	$317.1K	7	0.9%	8
6	Mebendazole	Antimalarial & Antiparasitic	$301.3K	13	2.2%	6
7	Enoxaparin	Cardiovascular	$300.0K	6	0.1%	19
8	Quinine	Antimalarial & Antiparasitic	$239.5K	6	1.2%	12

Cameg imports 8 pharmaceutical products across 5 categories into Cote D Ivoire totaling $5.3M.

Cameg — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

CAMEG, the Centrale d'Achat des Médicaments Essentiels Génériques et des Consommables Médicaux, is a non-profit organization established to ensure the availability and accessibility of essential generic medicines and medical consumables in Côte d'Ivoire. Operating under the Ministry of Health and Public Hygiene, CAMEG plays a pivotal role in the national healthcare supply chain by procuring, storing, and distributing pharmaceutical products to both public and private health facilities. This mission aligns with the government's objective to provide quality healthcare services to the population.

Headquartered in Abidjan, Côte d'Ivoire, CAMEG's operations are guided by the Direction de la Pharmacie, du Médicament et des Laboratoires (DPML), the country's pharmaceutical regulatory authority. The organization is committed to adhering to the regulatory frameworks established by the DPML, ensuring that all imported pharmaceutical products meet the required standards for safety, efficacy, and quality. CAMEG's strategic focus on essential medicines underscores its dedication to public health and its integral role in the nation's healthcare infrastructure.

2Distribution Network

CAMEG's distribution network is designed to ensure the efficient delivery of pharmaceutical products across Côte d'Ivoire. The organization operates a centralized warehouse located in Abidjan, which serves as the main hub for receiving, storing, and dispatching medical supplies. From this central point, products are distributed to various regional centers and health facilities throughout the country, ensuring that essential medicines are accessible to both urban and rural populations. This centralized approach allows for streamlined operations and effective inventory management, facilitating timely and reliable supply chain processes.

In addition to its domestic distribution capabilities, CAMEG engages in international procurement to source pharmaceutical products that are not locally available. This global sourcing strategy enables the organization to diversify its product offerings and meet the diverse healthcare needs of the Ivorian population. By leveraging both domestic and international supply chains, CAMEG enhances its capacity to provide a comprehensive range of medical supplies, contributing to the overall resilience and effectiveness of the country's healthcare system.

3Industry Role

Within Côte d'Ivoire's pharmaceutical supply chain, CAMEG functions primarily as a wholesaler and distributor. Its core responsibility is to procure and supply essential medicines and medical consumables to public and private health facilities, ensuring that these institutions have access to the necessary pharmaceutical products to deliver quality healthcare services. By centralizing the procurement and distribution processes, CAMEG aims to achieve economies of scale, reduce costs, and improve the efficiency of the healthcare supply chain. This centralized model also facilitates better inventory management and ensures a consistent supply of essential medicines across the country.

CAMEG's role extends beyond mere distribution; it also involves strategic planning and coordination with various stakeholders, including the Ministry of Health, healthcare providers, and international suppliers. This collaborative approach enables CAMEG to anticipate and respond to the evolving healthcare needs of the population, adapt to emerging health challenges, and implement initiatives that enhance the overall effectiveness of the healthcare system. Through its comprehensive and integrated approach, CAMEG plays a crucial role in maintaining the stability and reliability of Côte d'Ivoire's pharmaceutical supply chain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Cameg

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

CAMEG's sourcing strategy reveals a significant concentration in its supplier base, with a substantial portion of its pharmaceutical imports originating from a select group of Indian suppliers. The data indicates that the top five suppliers account for approximately 84.2% of the total import value, highlighting a dependency on these suppliers for the majority of its pharmaceutical products. This concentration suggests that CAMEG's procurement strategy is heavily reliant on a few key partners, which could pose risks related to supply chain disruptions, price fluctuations, or changes in supplier reliability.

The shipment data further illustrates the stability of these supplier relationships, with consistent and frequent shipments over the years. For instance, SIDHAANT LIFE SCIENCES PRIVATE LIMITED has been a dominant supplier, contributing 34.5% of the total import value through 188 shipments. Similarly, FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED has supplied 24.8% of the total import value across 131 shipments. This consistent engagement indicates a stable and ongoing partnership between CAMEG and these suppliers. However, the high concentration also underscores the potential vulnerability of CAMEG's supply chain to any disruptions affecting these key suppliers.

2Supply Chain Resilience

CAMEG's supply chain resilience is closely tied to its sourcing strategy, which is characterized by a high degree of concentration among a few key Indian suppliers. While this approach offers benefits such as streamlined procurement processes and established relationships, it also exposes CAMEG to potential risks. For example, any disruptions in the operations of these primary suppliers—such as production delays, quality issues, or geopolitical challenges—could significantly impact CAMEG's ability to maintain a consistent supply of essential medicines.

Importing Pharmaceuticals into Cote D Ivoire — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Cote D Ivoire

1Regulatory Authority & Framework

In Côte d'Ivoire, the regulation of pharmaceutical products is overseen by the Direction de la Pharmacie, du Médicament et des Laboratoires (DPML), which operates under the Ministry of Health and Public Hygiene. The DPML is responsible for ensuring that all pharmaceutical products imported into the country meet the required standards for safety, efficacy, and quality. This includes the registration and approval of pharmaceutical products, as well as the issuance of import authorizations. The regulatory framework established by the DPML is designed to protect public health by ensuring that only safe and effective pharmaceutical products are available in the Ivorian market.

The legal basis for the regulation of the pharmaceutical sector in Côte d'Ivoire is provided by Law No. 2017-541 of 3 August 2017. This law establishes the institutional and functional framework for the pharmaceutical regulatory system, aiming to guarantee the use of accessible, safe, effective, and high-quality pharmaceutical products. The law outlines the responsibilities of various stakeholders, including importers, exporters, and regulatory authorities, and sets forth the procedures for the import and export of pharmaceutical products. By adhering to this legal framework, CAMEG ensures compliance with national regulations and contributes to the overall integrity of the pharmaceutical supply chain in Côte d'Ivoire.

2Import Licensing & GMP

Frequently Asked Questions — Cameg

What products does Cameg import from India?

Cameg imports 8 pharmaceutical products across 5 categories. Top imports: Paracetamol ($2.5M), Ceftriaxone ($850.0K), Sulfamethoxazole ($400.0K), Trimethoprim ($400.0K), Griseofulvin ($317.1K).

Who supplies pharmaceuticals to Cameg from India?

Cameg sources from 37 verified Indian suppliers. The primary supplier is Sidhaant Life Sciences Private Limited (34.5% of imports, $5.7M).

What is Cameg's total pharmaceutical import value?

Cameg's total pharmaceutical import value from India is $5.3M, based on 115 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Cameg focus on?

Cameg imports across 5 categories. The largest: Analgesics & Antipyretics (47.1%), Advanced Antibiotics (31.1%), Antimalarial & Antiparasitic (10.2%).

Get Full Cameg Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.